11C-methionine PET for diagnoses of lung cancer and lymph node metastases in the mediastinum and pulmonary hilum: probability of prognostic prediction

11C-methionine PET for diagnoses of lung cancer and lymph node metastases in the mediastinum and pulmonary hilum: probability of prognostic prediction - 11C-methionine PET: probability of prognostic prediction in lung cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005096

Enrollment

Registered

2011-03-01

Start date

2009-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

To scan PET-CT after administering intravenously 11C-methionine in patients with lung cancer.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: preoperative patients with lung cancer

Exclusion criteria

Exclusion criteria: not getting informed consent from patients

Design outcomes

Primary

Measure	Time frame
The assessment of our study is to calculate SUVmax of primary lesion and lymph node metastasis on 11C-MET-PET, correlating with morphological evaluation using CT and histopathological evaluation.	—

Countries

Japan

Contacts

Public ContactJun Hatazawa

Osaka university graduate school of medicine Nuclear medicine

hatazawa@tracer.med.osaka-u.ac.jp06-6879-3461

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026